Mivelsiran: cAPPricorn-1 Study

Mivelsiran: cAPPricorn-1 Study

 

Mivelsiran: cAPPricorn-1 Study

The following information is provided in response to your unsolicited inquiry. It is intended to provide you with a review of the available scientific literature and to assist you in forming your own conclusions in order to make healthcare decisions. This document is not for further dissemination or publication without authorization.

The safety and efficacy of mivelsiran are currently being investigated in clinical studies and have not been evaluated by the FDA or any health authority.

If you are seeking additional scientific information related to Alnylam medicines, you may visit the Alnylam US Medical Affairs website at RNAiScience.com.

 Summary

      Mivelsiran targets intracellular and extracellular APP production in the CNS, upstream of amyloidogenic processing, through reduction of APP mRNA. The investigational hypothesis for mivelsiran suggests that the reduction of APP production causes the downstream Aβ protein species to be reduced. This downstream effect may thereby reduce amyloidogenic protein fragments and amyloid deposition in cerebral blood vessels.1

      The efficacy, safety, tolerability, and PD of mivelsiran in patients with sporadic or hereditary CAA are being evaluated in an ongoing, global, randomized, double-blind, placebo-controlled, phase 2 study (NCT06393712).2

Abbreviations

Aβ = amyloid beta; AD = Alzheimer’s disease; AE = adverse event; APP = Aβ precursor protein; BMI = body mass index; BOLD = blood oxygenation level dependent; CAA = cerebral amyloid angiopathy; CDR = clinical dementia rating; CI = cognitive impairment; CMB = cerebral microbleed; CNS = central nervous system; cSAH = convexity subarachnoid hemorrhage; CSF = cerebral spinal fluid; cSS = cortical superficial siderosis; EOAD = early onset Alzheimer's disease; eGFR = estimated glomerular filtration rate; ICH = clinical intracerebral hemorrhage; IQR = interquartile range; IT = intrathecal; MMSE = Mini‑Mental State Examination; MRI = magnetic resonance imaging; mRNA = messenger ribonucleic acid; OLE = open‑label extension; PD = pharmacodynamics; R = randomization; RNAi = ribonucleic acid interference; sAPPα = soluble amyloid precursor protein alpha; sAPPβ = amyloid precursor protein beta; SD = standard deviation; ULN = upper limit of normal

 Index

Study Design – Patient Demographics & Baseline Characteristics – References

 Study Design

The cAPPricorn-1 study is an ongoing, global, randomized, double-blind, placebo-controlled, phase 2 study designed to evaluate the efficacy, safety, tolerability, and PD of mivelsiran in patients with sporadic or Dutch-type CAA. Enrolled patients will be randomized to receive intrathecal injections of mivelsiran or placebo during the 24-month double-blind treatment period, followed by an optional 18‑month OLE period. The estimated duration of study participation, inclusive of the 60‑day screening period, the double-blind treatment period, the optional OLE, and the 6‑month additional safety follow‑up, is up to 50 months (Figure 1).1,2

Figure 1. cAPPricorn-1 Study Design.1

A diagram of a company

Description automatically generated with medium confidence

Abbreviations: CAA = cerebral amyloid angiopathy; IT = intrathecal; R = randomization.

aSporadic and Dutch-type CAA cohorts will be analyzed separately.

From Lee et al.1

The primary endpoint is the annualized rate of new lobar CMBs on brain MRI in patients with sporadic CAA.1

Secondary endpoints include1,2:

      Global rank based on severity, count, symptom burden, and timing of new clinical hemorrhagic events and hemorrhagic lesions on brain MRI

      Change from baseline in the total CAA small vessel disease score on brain MRI

      Incidence of new cerebral hemorrhagic lesions

      Assessment of vascular physiology through the change from baseline in cerebrovascular vasoreactivity on BOLD-fMRI

      Assessment of non-hemorrhagic disease progression through the incidence of white matter hyperintensities assessed on brain MRI

      Pharmacodynamic evaluation of the change from baseline in CSF sAPPα and sAPPβ concentrations

Safety will be assessed by the frequency of AEs in the double-blind treatment period and OLE for up to 48 months.1

Select study inclusion criteria include1:

      Able to complete MRI and tolerate lumbar puncture

      BMI ≥18 and ≤34 kg/m2

      Supportive psychosocial circumstances

      Sporadic CAA patients: ≥50 years with a probable CAA diagnosis per the Boston criteria version 2.0 with adaptations

      Dutch-type CAA patients: ≥30 years with a known E693Q APP gene variant

Select study exclusion criteria include1:

      Moderate or severe AD (CDR global score 2.0 or 3.0) or severe CI (MMSE <22)

      History of previous ICH with onset <90 days prior to randomization

      Any treatment with amyloid-targeting antibody

 Patient Demographics & Baseline Characteristics

Sporadic CAA Cohort

In the sporadic CAA cohort, a total of 170 patients were randomized and 168 patients received treatment (Table 1).3

Table 1. Baseline Characteristics of the Sporadic CAA Cohort in cAPPricorn-1.3

Characteristic

Sporadic CAA Cohort (N=168)

Age at informed consent, years, mean (SD)

71.8 (6.3)

Sex, male, n (%)

107 (63.7)

Race, n (%)a

 

Asian

1 (0.6)

Black or African American

3 (1.8)

White

160 (95.2)

Ethnicity, n (%)a

 

Hispanic or Latino

2 (1.2)

Not Hispanic or Latino

162 (96.4)

Comorbidities, n (%)

 

Hypertension

111 (66.1)

Hyperlipidemia/dyslipidemia

96 (57.1)

Coronary artery diseaseb

19 (11.3)

Atrial fibrillation/atrial flutter

14 (8.3)

Diabetes

11 (6.5)

Receiving acetylsalicylic acid, n (%)

25 (14.9)

Systolic/diastolic blood pressure, mmHg, mean (SD)

127.7 (13.4) / 73.7 (7.9)

Prior History of CAA-related clinically symptomatic hemorrhagic stroke,c n (%)

93 (55.4)

Primary, non-traumatic ICH, n (%)d

84 (50.0)

Acute cSAH, n (%)d

28 (16.7)

Transient focal neurological episodes,e n (%)

48 (28.6)

Cognitive impairment or dementia,e n (%)

123 (73.2)

CDR Global Score, n (%)f

 

0

39 (23.4)

0.5

111 (66.5)

1

17 (10.2)

MMSE score, median (IQR)

28.0 (25.5–29.0)

Abbreviations: CAA = cerebral amyloid angiopathy; CDR = Clinical Dementia Rating; cSAH = convexity subarachnoid hemorrhage; ICH = intracerebral hemorrhage; IQR = interquartile range; MMSE = Mini-Mental State Examination; SD = standard deviation.

aMissing, not reported, or other n=4 (2.4%).

bDefined as medical history of coronary artery disease, myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting.

cRepresents participants with symptomatic lobar ICH and symptomatic acute convexity subarachnoid hemorrhage.

dSome participants had both primary, non-traumatic ICH and acute cSAH.

eAcute transient focal neurological episodes and cognitive impairment/dementia are not mutually exclusive.

fn=167.

Imaging Parameters

In the sporadic CAA cohort, the baseline median (IQR) number of lobar CMBs was 40.5 (16.0-121.0). Out of the 168 patients, 26 patients had ≤9 lobar CMBs, 48 patients had 10-30 lobar CMBs, and 94 patients had ≥31 lobar CMBs at randomization.3

The baseline median (IQR) number of cSS foci was 2.0 (0.0-5.5). Out of the 168 patients, a total of 45 patients, 17 patients, 34 patients, 16 patients, and 56 patients had a multifocality rating score of 0, 1, 2, 3, and 4, respectively.3

References

1.  Lee J, van Etten ES, van Osch MJP, et al. Design and rationale of cAPPricorn-1, a phase 2 study of mivelsiran in patients with cerebral amyloid angiopathy. Presented at: Clinical Trials on Alzheimer’s Disease (CTAD) Conference; October 29–November 1, 2024; Madrid, Spain.

2.  Alnylam Pharmaceuticals: A phase 2 trial of ALN-APP in patients with cerebral amyloid angiopathy (cAPPricorn-1). Available from: https://clinicaltrials.gov/study/NCT06393712. Accessed October 2, 2026.

3.  Parikh NS, Deering R, He Y, et al. Baseline characteristics in cAPPricorn-1, a phase 2 study in cerebral amyloid angiopathy. Presented at: International Cerebral Amyloid Angiopathy (ICAA) Conference; September 15-17, 2026; Banff, Alberta, Canada.

 

Updated 06 October 2026

 

 

 

MED-ALL-APP-2400057 3.0 Approved through Oct 2028